URGN — UroGen Pharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1668243 ·
Last close
$38.24
Market Cap
$1.86B
52W High
$43.93
52W Low
$22.67
ADV30
745,727
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 50,959,000 | 46,820,000 | -20,263,000 | -23,574,000 | 253,690,000 | 109,968,000 | 377,943,000 |
| Dec 2025 | 37,837,000 | 34,548,000 | -19,115,000 | -26,364,000 | 200,455,000 | 110,745,000 | 305,929,000 |
| Sep 2025 | 27,482,000 | 24,204,000 | -27,386,000 | -33,347,000 | 185,046,000 | 90,039,000 | 300,454,000 |
| Jun 2025 | 24,215,000 | 20,665,000 | -41,448,000 | -49,940,000 | 208,717,000 | 92,904,000 | 302,093,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-162,444,000
Investing CF
$61,558,000
Financing CF
$39,918,000
CapEx
$-289,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.20
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-959,716,000
Inventory
$16,464,000
Receivables
$33,082,000
ST Investments
$9,711,000
EBIT TTM
$-138,071,000
Pretax Income TTM
$-153,416,000
Interest Exp TTM
$15,345,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$140,492,992
EBITDA
$-107,902,000
Free Cash Flow
$-109,282,248
Enterprise Value
$1,919,936,896
Total Cash
$140,274,000
Total Debt
$197,092,992
Shares Out
48,721,701
Trailing EPS
$-2.74
Book Value
$-2.55
ROE
—
ROA
-27.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 109,788,000 | -124,863,000 | -153,494,000 | 200,455,000 | 305,929,000 | — | -162,444,000 |
| Dec 2024 | 90,398,000 | -96,782,000 | -126,874,000 | 285,711,000 | 294,514,000 | — | -96,766,000 |
| Dec 2023 | 82,713,000 | -65,536,000 | -102,244,000 | 178,311,000 | 243,523,000 | — | -76,376,000 |
| Dec 2022 | 64,357,000 | -79,041,000 | -109,783,000 | 135,619,000 | 224,980,000 | — | -87,559,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.49
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HMDCF | HUTCHMED (China) Ltd | $1.88B | $2.16 | — |
| GLPGF | Lakefront Biotherapeutics NV | $1.84B | $28.08 | — |
| TYRA | Tyra Biosciences, Inc. | $1.90B | $31.88 | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.91B | $14.88 | — |
| GHRS | GH Research PLC | $1.93B | $28.07 | — |
News headlines (Yahoo Finance, 1h cache)
Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
2026-07-30 14:00 · Yahoo
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
2026-07-29 12:00 · Yahoo
Why Did CVS, URGN, CCK Stocks Hit 52-Week Highs Today?
2026-07-22 03:07 · Yahoo
Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027
2026-07-17 14:15 · Yahoo
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
2026-07-15 12:00 · Yahoo
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
2026-07-12 18:31 · Yahoo
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
2026-07-08 12:00 · Yahoo
Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?
2026-07-07 16:00 · Yahoo
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?
2026-07-01 03:58 · Yahoo
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
2026-06-23 14:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.